Synonyms: MK7762 | TBD09
Compound class:
Synthetic organic
Comment: MK-7762 (also known as TBD09) is the oxazolidinone antibacterial compound claimed in Merck's patent WO2021188606A1 [1]. It is being developed as a treatment for tuberculosis (TB) by Merck and the Bill & Melinda Gates Medical Research Institute.
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
methyl N-{[(5S)-3-[4-(1,1-dioxo-1λ6-thiomorpholin-4-yl)-3,5-difluorophenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl}carbamate |
Synonyms ![]() |
MK7762 | TBD09 |
Database Links ![]() |
|
Specialist databases | |
Antibiotic DB
![]() |
MK-7762 (TBD09) |
Other databases | |
CAS Registry No. | 2706576-88-5 (source: Scifinder) |
GtoPdb PubChem SID | 500839952 |
PubChem CID | 156857753 |
Search Google for chemical match using the InChIKey | CCYKSCLMFZLAJH-NSHDSACASA-N |
Search Google for chemicals with the same backbone | CCYKSCLMFZLAJH |
UniChem Compound Search for chemical match using the InChIKey | CCYKSCLMFZLAJH-NSHDSACASA-N |
UniChem Connectivity Search for chemical match using the InChIKey | CCYKSCLMFZLAJH-NSHDSACASA-N |